AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24001253 — intervention group
Group type: COMPARATOR
Intervention: Information on coworkers' usage levels
Number of subjects: 0
Study 20595146 — intervention group
Group type: EXPERIMENTAL
Intervention: SiNQ-5 questionnaire (self-administered, scoring 0-10 points)
Number of subjects: 125
Study 19201677 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face interview
Number of subjects: 818
Study 19201677 — intervention group
Group type: COMPARATOR
Intervention: Audio computer-assisted self-interview (audio-CASI)
Number of subjects: 818
Study 17217214 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing toothpaste containing EMS salts
Number of subjects: 40
Study 17217214 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothpaste (without any therapeutic agents)
Number of subjects: 40
Study 14623801 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural soluble CD40L (sCD40L) levels
Number of subjects: 70
Study 14623801 — intervention group
Group type: EXPERIMENTAL
Intervention: High preprocedural sCD40L
Number of subjects: 70
Study 14623801 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro stimulation with serum from patients with high sCD40L
Number of subjects: 70
Study 10757545 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg DHA/d for 3 months
Number of subjects: 28
Study 10757545 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg DHA/d for 3 months
Number of subjects: 28
Study 10757545 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg DHA/d for 3 months)
Number of subjects: 28
Study 8827810 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine administered orally twice a day
Number of subjects: 48
Study 8827810 — intervention group
Group type: COMPARATOR
Intervention: Control group (no azelastine)
Number of subjects: 48
Study 1424413 — intervention group
Group type: EXPERIMENTAL
Intervention: L-654,066 (0.1 mg)
Number of subjects: 48
Study 1424413 — intervention group
Group type: EXPERIMENTAL
Intervention: L-654,066 (0.5 mg)
Number of subjects: 48
Study 1424413 — intervention group
Group type: EXPERIMENTAL
Intervention: L-654,066 (1 to 25 mg)
Number of subjects: 48
Study 1424413 — intervention group
Group type: EXPERIMENTAL
Intervention: L-654,066 (50 to 100 mg)
Number of subjects: 48
Study 1424413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 29350278 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body resistance training with blood flow restriction (BFR) at 60% limb occlusion pressure
Number of subjects: 24
Study 29350278 — intervention group
Group type: COMPARATOR
Intervention: Non-BFR control group
Number of subjects: 24
Study 29350278 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body resistance training with blood flow restriction (BFR)
Number of subjects: 24
Study 27400292 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring balloon predilation
Number of subjects: 52
Study 27400292 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon predilation
Number of subjects: 52
Study 24338864 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measures of mental health and health insurance status
Number of subjects: 432
Study 23141372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 94
Study 23141372 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 94
Study 23141372 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone and Olanzapine
Number of subjects: 94
Study 20159249 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 248
Study 20159249 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 248
Study 19299087 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (1-session advice or motivational interviewing)
Number of subjects: 248
Study 19299087 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended intervention (10 sessions motivational interviewing/cognitive-behavior therapy)
Number of subjects: 248
Study 16476697 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled cervical epidural fentanyl (PCA-Epid group, n=20)
Number of subjects: 42
Study 16476697 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled i.v. fentanyl (PCA-IV group, n=22)
Number of subjects: 42
Study 16476697 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled cervical epidural fentanyl (PCA-Epid group)
Number of subjects: 42
Study 16476697 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled i.v. fentanyl (PCA-IV group)
Number of subjects: 42
Study 14508601 — intervention group
Group type: EXPERIMENTAL
Intervention: Pool-based exercise
Number of subjects: 50
Study 14508601 — intervention group
Group type: COMPARATOR
Intervention: Balneotherapy
Number of subjects: 50
Study 14508601 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 50
Study 11420782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol treatment (800 IU daily)
Number of subjects: 70
Study 11420782 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 70
Study 11420782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol treatment
Number of subjects: 70
Study 11420782 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal effect analysis
Number of subjects: 70
Study 9250233 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhalers
Number of subjects: 247
Study 9250233 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalers
Number of subjects: 247
Study 8513518 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg)
Number of subjects: 46
Study 8513518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 3646615 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased age
Number of subjects: 364
Study 3646615 — intervention group
Group type: EXPERIMENTAL
Intervention: DNR orders
Number of subjects: 364
Study 27287612 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard artemether-lumefantrine (AL) regimen + 0.25 mg/kg single-dose of primaquine (PQ)
Number of subjects: 220
Study 27287612 — intervention group
Group type: COMPARATOR
Intervention: Standard artemether-lumefantrine (AL) regimen
Number of subjects: 220
Study 24450819 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management to moderate hypothermia (32-34°C) for 72 hours
Number of subjects: 0
Study 24450819 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management to normothermia (36-37°C) for 72 hours
Number of subjects: 0
Study 24450819 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management to moderate hypothermia (32-34°C)
Number of subjects: 0
Study 24450819 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management to normothermia (36-37°C)
Number of subjects: 0
Study 22100962 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussions about burden of treatment (BOT) during clinical visits
Number of subjects: 46
Study 22100962 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussions about monitoring, treatment administration, access, and treatment effects
Number of subjects: 46
Study 22100962 — intervention group
Group type: EXPERIMENTAL
Intervention: Addressing burden of treatment (BOT)
Number of subjects: 46
Study 19397539 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% glucose infusion
Number of subjects: 121
Study 19397539 — intervention group
Group type: COMPARATOR
Intervention: 15% glucose infusion
Number of subjects: 121
Study 19702752 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (20-60 mg/kg/day)
Number of subjects: 99
Study 19702752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 19702752 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 99
Study 15845670 — intervention group
Group type: EXPERIMENTAL
Intervention: SAB+REMI (Spinal Anesthetic Blockade with Remifentanil)
Number of subjects: 45
Study 15845670 — intervention group
Group type: COMPARATOR
Intervention: REMI (Remifentanil without Spinal Anesthetic Blockade)
Number of subjects: 45
Study 12875347 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril/hydrochlorothiazide (20 mg/12.5 mg)
Number of subjects: 24
Study 10484594 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-Intensity (VI) exercise
Number of subjects: 6
Study 10484594 — intervention group
Group type: COMPARATOR
Intervention: Constant-Load (SS) exercise
Number of subjects: 6
Study 8753675 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoactivation with acetazolamide
Number of subjects: 80
Study 8753675 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroactivation by labyrinth task
Number of subjects: 80
Study 1878244 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dimetindene gel
Number of subjects: 52
Study 1878244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 6798903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 10
Study 6798903 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 10
Study 6798903 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 10
Study 30508141 — intervention group
Group type: EXPERIMENTAL
Intervention: cCBT (computerized cognitive behavioral therapy) intervention, Beating the Blues, with care coach support for eight sessions
Number of subjects: 30
Study 30508141 — intervention group
Group type: EXPERIMENTAL
Intervention: cCBT (computerized cognitive behavioral therapy) intervention
Number of subjects: 30
Study 30508141 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 30
Study 30722757 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair-based aerobic exercises (CAE, n = 19)
Number of subjects: 47
Study 30722757 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair-based elastic-band strength exercises (CSE, n = 15)
Number of subjects: 47
Study 30722757 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 13)
Number of subjects: 47
Study 28106355 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic-guided intubation (FGI)
Number of subjects: 32
Study 28106355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway assisted intubation (ILMA-AI)
Number of subjects: 32
Study 26013537 — intervention group
Group type: COMPARATOR
Intervention: Tobacco only intervention (n=199)
Number of subjects: 620
Study 26013537 — intervention group
Group type: COMPARATOR
Intervention: Alcohol only intervention (n=206)
Number of subjects: 620
Study 26013537 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated alcohol and tobacco intervention (n=215)
Number of subjects: 620
Study 26013537 — intervention group
Group type: COMPARATOR
Intervention: Control group (tobacco only intervention)
Number of subjects: 620
Study 26013537 — intervention group
Group type: COMPARATOR
Intervention: Control group (alcohol only intervention)
Number of subjects: 620
Study 23212677 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured intervention consisting of psychoeducation and cognitive behavioral therapy (6 one-hour sessions with a psychologist)
Number of subjects: 56
Study 23212677 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 56
Study 21321787 — intervention group
Group type: EXPERIMENTAL
Intervention: Job maintenance training program
Number of subjects: 122
Study 21321787 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 122
Study 19477443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal instillation of 120 mg of lidocaine
Number of subjects: 75
Study 19477443 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 75
Study 16927437 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmatched analysis on data from matched-pair design
Number of subjects: 0
Study 16927437 — intervention group
Group type: COMPARATOR
Intervention: Matched analysis
Number of subjects: 0
Study 16927437 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized linear model approach
Number of subjects: 0
Study 16927437 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage cluster-level analysis
Number of subjects: 0
Study 16927437 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equations
Number of subjects: 0
Study 13678227 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Fennel extract cream
Number of subjects: 38
Study 13678227 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Fennel extract cream
Number of subjects: 38
Study 13678227 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0% Fennel extract cream)
Number of subjects: 38
Study 10633537 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I diabetic patients with history of recurrent severe hypoglycaemia
Number of subjects: 41
Study 10633537 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I diabetic patients without history of severe hypoglycaemia
Number of subjects: 41
Study 10633537 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic controls
Number of subjects: 41
Study 9192125 — intervention group
Group type: EXPERIMENTAL
Intervention: Random urine testing for performance enhancing drugs (anabolic steroids, diuretics, caffeine, peptide hormones, pseudoephedrine, probenecid, methoxyphenamine, dextropropoxyphene)
Number of subjects: 900
Study 1300947 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotics (latamoxef, cefmenoxime, cefotiam, cefamandole) administered during operation at a dose of 1 or 2 g
Number of subjects: 80
Study 1300947 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotics (cefem antibiotics) administered by intravenous drip at a dose of 1 or 2 g, twice daily for 4 to 7 days postoperatively
Number of subjects: 80
Study 3818070 — intervention group
Group type: EXPERIMENTAL
Intervention: New support
Number of subjects: 144
Study 3818070 — intervention group
Group type: COMPARATOR
Intervention: Double Tubigrip
Number of subjects: 144
Study 3818070 — intervention group
Group type: COMPARATOR
Intervention: Eversion strapping
Number of subjects: 144
Study 29618501 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwell plate (MWP) version of the Roche HIV-1 Monitor test
Number of subjects: 1570
Study 29618501 — intervention group
Group type: COMPARATOR
Intervention: Cobas version of the assay
Number of subjects: 1570
Study 27137709 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology interventions (3 different 6-week face-to-face interventions)
Number of subjects: 55
Study 27137709 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 55
Study 25164991 — intervention group
Group type: EXPERIMENTAL
Intervention: Studied items
Number of subjects: 0
Study 25164991 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemplar items
Number of subjects: 0
Study 25164991 — intervention group
Group type: EXPERIMENTAL
Intervention: Category-wide neural suppression
Number of subjects: 0
Study 25164991 — intervention group
Group type: EXPERIMENTAL
Intervention: Item-specific neural suppression
Number of subjects: 0
Study 22949162 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental neuromyotherapy combined with standard therapy
Number of subjects: 24
Study 22949162 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 24
Study 20974574 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole buccal tablet (MBT) 50 mg once daily
Number of subjects: 578
Study 20974574 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole troches (CT) 10 mg 5 times daily
Number of subjects: 578
Study 18838664 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-plane technique comparing each eye's velocity as a function of normalized displacement in patients with INO, oculomotor or abducens nerve palsy, and advanced extraocular muscle disease.
Number of subjects: 22
Study 18838664 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-plane technique comparing each eye's velocity as a function of normalized displacement in patients with disease affecting the neuromuscular junction.
Number of subjects: 22
Study 18838664 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-plane technique comparing each eye's velocity as a function of normalized displacement in patients with pontine lesions.
Number of subjects: 22
Study 18838664 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects making disconjugate saccades between two targets aligned on one eye.
Number of subjects: 22
Study 15751170 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel + cisplatin
Number of subjects: 0
Study 12057879 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective preference assessment (PPA) method
Number of subjects: 0
Study 12057879 — intervention group
Group type: COMPARATOR
Intervention: Traditional informed consent process
Number of subjects: 0
Study 10563682 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents with disfiguring burn scars
Number of subjects: 14
Study 8588407 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopically controlled suctioning
Number of subjects: 40
Study 8588407 — intervention group
Group type: COMPARATOR
Intervention: Blind suctioning
Number of subjects: 40
Study 1961024 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentostatin
Number of subjects: 5
Study 1961024 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-interferon
Number of subjects: 5
Study 7324992 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate (20 mg every 2-3 weeks)
Number of subjects: 126
Study 7324992 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 126
Study 30826253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 57
Study 30826253 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 57
Study 28931394 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive mechanical ventilation (NIV)
Number of subjects: 0
Study 28931394 — intervention group
Group type: COMPARATOR
Intervention: Invasive mechanical ventilation (IMV)
Number of subjects: 0
Study 25460384 — intervention group
Group type: EXPERIMENTAL
Intervention: High inhibition demands through prolonged and intensive practice of the Simon or Eriksen Flanker task
Number of subjects: 0
Study 23957307 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry face (singleton)
Number of subjects: 0
Study 23957307 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy face (singleton)
Number of subjects: 0
Study 23957307 — intervention group
Group type: COMPARATOR
Intervention: Neutral faces
Number of subjects: 0
Study 22294641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate 4.5 g/night
Number of subjects: 573
Study 22294641 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate 6 g/night
Number of subjects: 573
Study 22294641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 573
Study 18946484 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg day(-1)
Number of subjects: 195
Study 18946484 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg day(-1)
Number of subjects: 195
Study 18946484 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 195
Study 18946484 — intervention group
Group type: COMPARATOR
Intervention: Rilmenidine 1 mg day(-1)
Number of subjects: 195
Study 18946484 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg day(-1)
Number of subjects: 195
Study 17467226 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical compression stockings (23 to 32 mm Hg) worn daily for 3 weeks
Number of subjects: 100
Study 17467226 — intervention group
Group type: COMPARATOR
Intervention: No compression stockings (control group)
Number of subjects: 100
Study 15711683 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 32
Study 15711683 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 32
Study 11784251 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-based anesthesia
Number of subjects: 100
Study 11784251 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 100
Study 11784251 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 9855323 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim administration after chemotherapy
Number of subjects: 2
Study 9855323 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy started within 72 hours of filgrastim therapy
Number of subjects: 2
Study 7907729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (500 mg/m2, three times a day for 1 month) followed by oral acyclovir (800 mg four times a day for 6 months)
Number of subjects: 310
Study 7907729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir followed by oral placebo
Number of subjects: 310
Study 7907729 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral acyclovir (200 or 400 mg, four times a day) followed by placebo
Number of subjects: 310
Study 2534054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium (80 micrograms applied intranasally four times daily)
Number of subjects: 20
Study 2534054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2534054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 20
Study 7352836 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable fluphenazine decanoate
Number of subjects: 290
Study 7352836 — intervention group
Group type: COMPARATOR
Intervention: Short-acting oral fluphenazine hydrochloride
Number of subjects: 290
Study 7352836 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 290
Study 7352836 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine hydrochloride
Number of subjects: 290
Study 30113196 — intervention group
Group type: EXPERIMENTAL
Intervention: Current conjecture group
Number of subjects: 432
Study 30113196 — intervention group
Group type: COMPARATOR
Intervention: Reproduced conjecture group
Number of subjects: 432
Study 30113196 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled lab experiment
Number of subjects: 432
Study 28394819 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet atmosphere during SCT assessment
Number of subjects: 42